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Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex chronic
condition affecting multiple body systems, with unknown cause, unclear pathogenesis
mechanisms, and fluctuating symptoms which may lead to severe debilitation. It is
frequently reported to have been triggered by an infection, but there are no clear
differences in exposure to, or seroprevalence of, any particular viruses between people
with ME/CFS and healthy individuals. However, herpes viruses have been repeatedly
hypothesized to underlie the chronic relapsing/remitting form of MS/CFS due to their
persistence in a latent form with periodic reactivation. It is possible that ME/CFS is
associated with herpes virus reactivation, which has not been detectable previously
due to insufficiently sensitive testing methods. Saliva samples were collected from 30
people living with ME/CFS at monthly intervals for 6 months and at times when they
experienced symptom exacerbation, as well as from 14 healthy control individuals. The
viral DNA load of the nine humanherpes viruses was determined by digital droplet PCR.
Symptoms were assessed by questionnaire at each time point. Human herpesvirus
(HHV) 6B, HHV-7, herpes simplex virus 1 and Epstein-Barr virus were detectable within
the saliva samples, with higher HHV-6B and HHV-7 viral loads detected in people
with ME/CFS than in healthy controls. Participants with ME/CFS could be broadly
separated into two groups: one group displayed fluctuating patterns of herpesviruses
detectable across the 6 months while the second group displayed more stable viral
presentation. In the first group, there was positive correlation between HHV-6B and
HHV-7 viral load and severity of symptom scores, including pain, neurocognition, and
autonomic dysfunction. The results indicate that fluctuating viral DNA load correlates
with ME/CFS symptoms: this is in accordance with the hypothesis that pathogenesis is
related to herpesvirus reactivation state, and this should be formally tested. Herpesvirus
reactivation might be a cause or consequence of dysregulated immune function seen
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in ME/CFS. The sampling strategy and molecular tools developed here permit such
large-scale epidemiological investigations.
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INTRODUCTION
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
(ME/CFS) is a disease of unknown aetiology, causing persistent,
or recurrent incapacitating fatigue; a hallmark symptom is post-
exertional malaise (PEM). Other symptoms, which are present
to a varying degree in different individuals, include pain and
disturbances in immune function along with lymphadenopathy,
unrefreshing sleep, cognitive difficulties, and dysfunction of
the endocrine and autonomic nervous systems (1, 2). Despite a
prevalence in Europe ranging from 0.1 to 2.2% (3), there is still
no diagnostic test for ME/CFS, hampering research into its cause
and pathogenesis, and development of treatments. While the risk
of developing ME/CFS is likely to be multifactorial, in ∼50% of
cases ME/CFS symptoms appear after a “viral-like” illness, and it
is possible that an infectious disease can trigger ME/CFS onset.
However, no single causative pathogen has been identified for
ME/CFS, despite extensive research (4).
Although, there have been reports that bacterial infections
such as Lyme disease (5) or Q fever (6) can trigger ME/CFS, it
is mostly commonly viral infections, especially those from the
herpesvirus family, which have been more widely associated with
ME/CFS (4). There are nine members of the human herpesvirus
(HHV) family which naturally infect humans: herpes simplex
virus-1 and -2 (HSV-1, HSV-2), varicella-zoster virus (VZV),
which is the causative agent of chicken pox and shingles, Epstein-
Barr virus (EBV), which causes of infectious mononucleosis,
human cytomegalovirus (HCMV), HHV-6 including subtypes
HHV-6A and HHV-6B, HHV-7, and Kaposi’s sarcoma virus
(KSHV). These viruses are all of potential interest in ME/CFS
due to their ability to latently infect either neurons or immune
system cells, both of which may be affected in ME/CFS. There
has been speculation that Epstein-Barr Virus (EBV) is involved
in ME/CFS pathogenesis for many years (7, 8), although, reports
are inconsistent (9, 10). Reports of the potential involvement
of CMV in ME/CFS are also mixed, with higher anti-CMV
antibodies reported in serum in ME/CFS compared to healthy
controls (HCs) in one study (11) but no correlation in another
(12). HHV-6 and HHV-7, which are from the Roseolovirus genus
of the Beta-herpesvirinae subfamily, cause widespread long-
term persistent infection with reported population prevalence
of >90% (13) with infection usually occurring within the first
3 years of life. In early studies, there was serological indication
of HHV-6 reactivation with higher specific anti-HHV-6 serum
antibody concentration in people living with ME/CFS than in
HCs (14, 15) but these data have been contradicted in other
studies (16). Similarly, HHV-7 infection is commonly detectable
in people living with ME/CFS, but the detection rate of HHV-7
DNA is similar in ME/CFS patients and in HCs (17).
Thus, reports of association between herpesvirus infection
and/or reactivation and ME/CFS are inconsistent. This may
be due partly to small sample sizes in some studies, and
to heterogeneity within and between ME/CFS populations
included in different studies. We did not find any difference in
seroprevalence or antibody titres against the eight herpesviruses
between people living with ME/CFS and HCs in our previous
work (18). However, a hallmark feature of herpes viruses is their
life cycle in which, following an acute infection, they remain in
the host in a latent persistent form, and can reactivate following
immune system disturbance. Measurements of antibody titre
by ELISA and qPCR analysis of viral DNA concentration in
blood may be too insensitive to fully distinguish reactivation
events from latent infection, and a more sensitive analysis might
enable the full characterisation of herpesvirus reactivation events
in ME/CFS, leading to a definitive answer regarding the role
of herpesvirus infections in this condition. Digital droplet PCR
(ddPCR) permits absolute quantification of nucleic acids (19).
This is achieved via an emulsion process in which the fluorescent
probe-based PCR reaction is partitioned into ∼15,000 highly
uniform, one nanolitre volume, reverse (water-in-oil) micelles
that are stable at high temperatures: each droplet is essentially an
independent nano-PCR. Enumeration of the number of positive
and negative droplets post-PCR gives a sensitive and precise
readout of the template DNA concentration.
In this study, we hypothesised that ME/CFS may either follow
an acute infection with a herpes virus, with symptoms being
triggered by a virus reactivation followed by a state of “aberrant
homeostasis” (20), or that in people with ME/CFS due to another
cause (infectious or not) reduced control of herpes virus latency
leads to periodic reactivation and exacerbation of symptoms.
Although, herpes virus infections are common, it is possible
that people living with ME/CFS experience prolonged or more
frequent reactivation events than healthy individuals and are
unable to consistently contain a latent infection. We aimed
to develop highly sensitive and specific ddPCR assays for the
humanherpes family viruses, and use them to test for correlation
between viral load in saliva, an accessible sample likely to be
involved in transmission (16), and the clinical manifestations of
disease over time, particularly during disease exacerbation.
MATERIALS AND METHODS
Study Participants
Potential ME/CFS study participants were recruited to the UK
ME/CFS Biobank (UKMEB) (21) through the UK National
Health Service or referred via patient support groups with
ME/CFS. They were required to have a confirmed medical
diagnosis of ME/CFS and were re-assessed by clinical research
staff to ensure compliance with the Canadian Consensus (22)
and/or CDC-1994 (“Fukuda”) (1) criteria, which were the study
case definitions. Non-fatigued HC participants were recruited as
friends or family of people with ME/CFS or by advertisement
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in Higher Education Institutions and GP practices. Participants
were aged between 18 and 60 years and provided written
informed consent. Exclusion criteria included having taken
anti-viral or immunomodulatory drugs within the previous 3
months, chronic comorbid disease (including hypothyroidism;
hyperthyroidism; cancer; rheumatoid arthritis; fibromyalgia;
other serious rheumatic disease, such as lupus or polymyositis
(but not osteoarthritis); heart disease, (such as heart failure);
severe COPD or other severe ongoing respiratory disease;
severe anaemia; kidney failure; diabetes; Addison’s or Cushing’s
disease; any of bipolar disorder, schizophrenia, major depression,
anorexia, or bulimia; multiple sclerosis; Parkinson’s Disease;
Myasthenia Gravis or other serious neurological disease (except
for ME/CFS); sleep apnoea/narcolepsy), a history of infectious
disease such as tuberculosis or hepatitis B or C, excessive
consumption of alcohol or recreational drugs, pregnancy, and
morbid obesity. Inclusion criteria included HHV DNA detected
in either plasma or PBMC (DNA positive) or HHV DNA not
detected in either sample (DNA negative (as described below,
5.2). Ethical approval was granted by the London School of
Hygiene & Tropical Medicine (LSHTM) Ethics Committee (Ref.
6123) and the National Research Ethics Service (NRES) London-
Bloomsbury Research Ethics Committee (REC ref. 11/10/1760,
IRAS ID:77765). Peripheral Blood Mononuclear Cells (PBMC)
and plasma samples were cryopreserved and stored from all
UKMEB participants (21) and accessed for this study.
Longitudinal Analysis
Selected participants from the UKMEB cohort provided further
written informed consent for this longitudinal study. Participants
were sent GeneFiXTM Saliva 2ml DNA Collection tubes
containing DNA stabilisation buffer and asked to return filled
saliva tubes by post monthly for 6 months as well as on the first,
third and fifth day of any disease exacerbation episode including
acute illness or significant worsening of ME/CFS symptoms.
Clinical symptom assessment forms
(Supplementary Figure 1), containing 58 questions with graded
answers, were completed and returned at the same time as
each saliva sample. From these data, symptom subgroup scores
were developed, for immune, neuroendocrine, autonomic,
neurocognition, pain, sleep, and post-exertional related
symptoms; the Canadian Consensus Criteria assesses these
domains for ME/CFS diagnosis (22). The scores ranging from
“0” to “100” represent a weighted average of the reported
symptoms on each domain, which are reported as “absent, mild,
moderate, or severe.”
DNA Extraction and Digital Droplet PCR
DNA was extracted from stored plasma samples using the
QIAamp MinElute Virus Spin Kit (Qiagen), and from PBMC
and saliva using the QIAamp DNAMini Kit (Qiagen), according
to the manufacturer’s instructions. Each DNA extraction run
included a seronegative control sample and a Clinical Virology
Multiplex I [National Institute for Biological Standards and
Control (NIBSC)] positive extraction control: this comprised
Adenovirus serotype 2, BK virus, CMV, EBV, HSV-1, HSV-2,
HHV-6A, HHV-6B, JC virus, Parvo B19 virus, and VZV.
For assay development and to generate standard curves,
titrated commercial quantitated DNA was used: HSV-1, HSV-2,
VZV, & HHV-8 were purchased from Vircell (Granada, Spain),
HHV-6A, HHV-6B, and HHV-7 were from ABI (Advanced
Biotechnologies Inc, MD, USA) while EBV and CMV were
from the National Institute for Biological Standards and
Control (NIBSC).
Each 20 µl ddPCR reaction mix contained 10 µl ddPCRTM
Supermix for Probes (Bio-Rad Laboratories, Hercules, USA), 9
µl of template DNA, 1 µl of 20X primer and probe mix at a final
concentration 900 nM (for primer) and at 250 nM (for probe).
Positive (commercial viral DNA) and negative (water) controls
were included in every ddPCR run. Primer and probe sequences
are shown in Supplementary Table 1, and were obtained from
publications (23–28). The reaction mix was partitioned in oil-
in-water with 70 µl of droplet generator oil using a QX-100
droplet generator (Bio-Rad). The generated droplets (around 40
µl) were transferred to ddPCRTM 96-Well Plates (Bio-Rad) using
a multichannel pipette and covered with a pierceable PCR plate
seal using a PX1TM PCR Plate Sealer (Bio-rad). PCR amplification
was performed with the following thermal cycling: 95◦C for
10min, 40 cycles consisting of 94◦C for 30 sec (denaturation)
and 60◦C for 1min (extension), followed by 98◦C for 10min and
holding at 12◦C. After that, droplets (positive and negative) were
analysed using a QX100 droplet reader (Bio-rad) and the target
DNA concentration was calculated and presented as copies/µl in
the reaction mixture using QuantaSoft software (Bio-Rad). The
ddPCR result was determined as positive when the DNA samples
showed at least three positive droplets from 10,000 to 15,000
droplets, according to the manufacturer’s recommendation.
Herpesvirus Serology
Commercial ELISA kits were used to measure plasma
concentrations of IgG to HSV-1, HSV 2, VZV, HCMV,
EBV viral capsid antigen (VCA), EBV nuclear antigen 1
(EBNA 1) [from Demeditec Diagnostics (Kiel, Germany)] and
HHV-6 [from VIDIA (Vestec, Czech republic)]: these data
have been reported previously (18), and are included here for
comparison. The antibody concentrations were calculated from
standard curves. For qualitative evaluation of IgG antibodies
to HSV-1, HSV-2, VZV, CMV, EBV VCA, EBV, EBNA-1, the
concentration was interpreted as: concentration ≤8 U/ml =
negative, concentration ≥12 U/ml= positive, and concentration
between 8 and 12 U/ml = equivocal. For qualitative evaluation
of IgG antibodies to HHV-6, concentration ≤10.5 U/ml was
considered negative, while concentration ≥12.5 U/ml was
considered positive and concentration between 10.5 and 12.5
was considered equivocal.
Data Analysis
Statistical analysis was conducted using GraphPad Prism 8.4.2
(GraphPad Software, San Diego, CA). Continuous variables (viral
loads, viral persistency and symptom scores) were described
using median and interquartile ranges (IQR) values or min
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FIGURE 1 | DNA concentration measured by ddPCR assays for the nine human herpes viruses. (A) Example 1D dot plot data file for HHV-6A and HHV-6B ddPCR
assays. The X-axes show quantities of commercial viral DNA in different assay plate wells (E02, F02, G02, etc.,). Assays were run either singly or in duplex as shown.
The Y-axes indicate the fluorescence intensity within each PCR droplet, with the pink line indicating the threshold for positivity. (B) Example representation of 2D dot
plot displaying duplex ddPCR of HHV-6B (FAM labelled, channel 1) and HHV-6A (HEX labelled, channel 2). (C) Standard curves obtained for each of the nine human
herpesviruses, indicating the concentration of serial dilutions of commercial DNA on the X-axes, and the calculated concentration of viral DNA from the ddPCR assay
on the Y-axes.
to max as indicated. Mann-Whitney test was used for viral
load comparison of each HHV between clinical groups. The
frequencies of HHV were compared using the chi-square test.
For correlation analysis between HHV viral load and numerical
clinical symptom scores or IgG titre from serological tests, the
Spearman’s correlation was utilised. Differences where P < 0.05
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FIGURE 2 | Flow diagram of participant recruitment and follow up in the longitudinal saliva clinical study. Serological test (n = 235) and consecutive ddPCR assay in
the plasma (n = 189) and PBMC (n = 76) were performed for HHV screening purposes. In total, 46 participants were enrolled into a 6-month longitudinal study to
determine salivary HHV. Saliva samples (monthly and day 1, 3, and 5 of an acute illness or worsening of disease episode in people with ME/CFS, n = 276) were then
analysed for HHV DNA concentration by ddPCR assay, with results compared with symptoms scores. *30 participants were tested for both plasma and PBMC.
are deemed significant, and in graphs ∗indicates P < 0.05, ∗∗P <
0.01, ∗∗∗P < 0.001.
RESULTS
Development of Sensitive and Specific
ddPCR Assays for Human Herpes Viruses
For each of the nine members of the human herpes family
of viruses, ddPCR assays were designed to run in duplex
using specific primers and probes which were coupled to
either FAM or HEX reporter labels (Supplementary Table 1).
Examples of single and duplex ddPCR assays for HHV-
6A and HHV-6B are shown in Figure 1A, with different
proportions of positive and negative droplets reflecting
the starting concentration of commercial DNA. In duplex
assays spiked with both HHV-6A and HHV-6B DNA, the
majority of ∼15,000 droplets measured were PCR-negative
for both viruses, with substantial positivity observed for
each individual virus but very few droplets deemed to
have dual positivity (Figure 1B), as expected. Reproducible
precise standard curves were obtained for each of the human
herpesviruses (Figure 1C). Of note, the viral DNA copy number
detected by ddPCR for HHV-7 and VZV was lower than
the commercial DNA quantity description, over-estimates of
DNA concentration by absorbance spectrophotometry are
common (29).
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Study Participant Selection: Detection of
Human Herpes Virus DNA in Plasma and
PBMC
The aim of the longitudinal clinical study was to test whether
the concentration of HHV DNA in saliva reflected disease
severity: in order to achieve this, we needed to identify
potential participants who had previously been exposed to HHVs
(Figure 2). Previously (18), concentrations of IgG antibodies
against HSV-1, HSV-2, VZV, EBV, CMV and HHV-6 in plasma
samples from 132 people with ME/CFS, 76 HC participants
and 27 people with multiple sclerosis (MS) in the UKMEB
were measured by ELISA. Serum samples (189) with high
IgG titre to CMV (≥90 U/ml) or EBV (≥150 U/ml for VCA
or ≥90 U/ml for EBNA), or that were seropositive to ≥
five out of six HHVs measured, were screened by ddPCR
to detect potential active (lytic) replication of any of the
nine HHVs. HHV DNA was rarely detected, with HSV-2,
HHV-6A and HHV-6B detected in plasma from one or two
subjects and the remaining HHVs always negative (Table 1).
We therefore, screened PBMC samples, which were available
from 76 potential participants; EBV was detected in 8 subjects,
CMV in 1 subject and HHV-7 in 25 subjects (Table 1), probably
reflecting latent infection. A single HHV DNA was detected
in most cases of DNA positivity, whereas, co-detection of
HHVs occurred in three individuals (1 HC: CMV &HHV-
7; 2 ME/CFS_SA: EBV & HHV-7) (Supplementary Table 2).
There was no significant correlation between EBV DNA copy
number and either anti-EBNA 1 IgG (P = 0.64) or anti-
VCA IgG (P = 0.19), possibly due to low DNA positivity
rates. Correlation between HHV-7 DNA copy number and IgG
concentration could not be tested, due to lack of serological
assay availability. The participant characteristics are shown in
Supplementary Table 2.
Longitudinal Study: Clinical Analysis of
HHVs in Saliva From People Living With
ME/CFS
Candidates were selected for invitation to participate in the
longitudinal study of saliva HHV (Figure 2) if any HHV
DNA was detected in either plasma or PBMC (DNA positive)
or if HHV DNA was not detected in either sample (DNA
negative); all invited participants were seropositive for all six
HHVs tested. MS patients, who also have samples stored in the
UK ME/CFS Biobank, were not included in the longitudinal
study due to low HHV DNA positivity in plasma and PBMC.
A total of 70 candidates were invited to participate in the
study, of whom 46 were enrolled; their blood DNA results
reflected those of the group as a whole (Supplementary Table 2).
Participants were requested to post a saliva sample and a
completed patient questionnaire (Supplementary Figure 1)
to LSHTM monthly for 6 months, and on the first, third
and fifth day of any disease exacerbation episode including
acute illness or significant worsening of ME/CFS symptoms.
From December 2017 to June 2018, 276 saliva samples were
collected. The monthly sampling return rate was 92.7, 83.3, and
97.9% in HC, ME/CFS_MM (mild/moderate) and ME/CFS_SA
(severely affected) groups, respectively. Additionally, one
ME/CFS_MM and six ME/CFS_SA participants sent
samples during episodes of acute illness/worsening of
symptoms: one ME/CFS_SA sent samples for two episodes
(Figure 2).
As anticipated, the symptom questionnaires revealed
absent or mild symptoms across all the domains in the
healthy participants, with the exception of Sleep Dysfunction,
which was reported at mild to moderate levels in over
half the group at some points during the study period
(Supplementary Figure 2). In contrast, all participants reported
a wide variety of symptoms across all the domains, ranging
from mild to severe and fluctuating through the 6 months.
Post-exertional malaise, neurocognitive, autonomic, and
immune system dysfunctions were reported as more severe
in the severely affected participants, whereas, pain, sleep and
neuroendocrine dysfunction were more similarly reported
across participants with mild/moderate or severe ME/CFS
(Supplementary Figure 2).
HHV Prevalence and Persistence Over
Time in Saliva From People With ME/CFS
The concentration of DNA for each of the nine HHVs was
measured in saliva samples fromME/CFS patients (14MM cases;
16 SA cases) and 16 HCs by ddPCR and the prevalence and
shedding pattern of HHVs investigated over time. Throughout
the study time course, HSV-1, EBV, HHV-6B, and HHV-
7 were detected in at least some participants, whereas, the
remaining HHVs were undetectable throughout. Most saliva
samples contained one, two or three HHVs. At the start of the
study (month 1), HHV-7 was the most prevalent HHV in saliva
of all participants, whereas, HSV-1 was detected from only 1
participant in each group (Figure 3A) and the prevalence of EBV
and HHV-6B differed between the groups (EBV: 56% (9/16) in
HC, 29% (4/14) in ME/CFS_MM, 38% (6/16) in ME/CFS_SA;
HHV-6B: 25% (4/16) in HC, 29% (4/14) in ME/CFS_MM,
56% (9/16) in ME/CFS_SA). HHV prevalence remained largely
unchanged throughout the 6 months of follow up with HHV-
6B being the only virus to differ in prevalence between the
groups, being borderline significantly more highly prevalent
in severely affected ME/CFS patients than in healthy controls
(Supplementary Table 3).
To investigate viral persistence, the proportion of samples
from each participant that were HHV-positive over the time
course was determined (Figure 3B). HHV-7 was consistently
detected in all samples from the majority of participants
throughout the 6 months (median for all 3 groups = 100%),
whereas, HSV-1, EBV, and HHV-6B were only intermittently
detected. HHV-6B was detected significantly more frequently in
the ME/CFS_SA participants (median: 33.3%, IQR: 16.7–75%),
than in HC (median: 8.33%, IQR: 0–41.7%; p = 0.049), but not
in ME/CFS_MM participants (median: 22.5%, IQR: 0–70.8%;
p = 0.28). In contrast, there was no significant difference in the
frequency of detection of EBV or HSV-1 in HC compared to
people with ME/CFS (Figure 3B).
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PLASMA Positive 0 – 0 – 0 – 0 –
Negative 115 131.00 62 4.60 12 10.19
PBMC Positive 0 – 0 – 0 – 0
Negative 34 115.70 40 2.34 2 9.91
HSV-2
PLASMA Positive 0 – 1 2.87 0 – 0.5 MS (1)
Negative 100 93.45 82 2.84 6 10.50
PBMC Positive 0 – 0 – 0 – 0
Negative 30 99.33 44 3.10 2 10.97
VZV
PLASMA Positive 0 – 0 – 0 – 0 –
Negative 184 143.58 4 7.54 1 10.76
PBMC Positive 0 – 0 – 0 – 0
Negative 74 126.92 3 8.79 0 –
EBV (anti VCA IgG)
PLASMA Positive 0 – 0 – 0 – 0 HC (3), ME/CFS_MM
(2), ME/CFS_SA (3)Negative 169 156.65 13 4.71 0 –
PBMC Positive 8 120.26 0 – 0 – 11.7
Negative 58 120.65 8 2.60 2 8.71
EBV (anti EBNA-1 IgG)
PLASMA Positive 0 – 0 – 0 – 0 *HC (2), ME/CFS_MM
(2), ME/CFS_SA (1)Negative 140 55.42 35 5.95 7 9.52
PBMC Positive 5* 47.93 2# 4.92 1∼ 8.58 11.7 #HC (1), ME/CFS_SA (1)
∼ME/CFS_SA (1)Negative 50 50.56 13 5.68 5 11.25
CMV
PLASMA Positive 0 – 0 – 0 – 0 HC (1)
Negative 94 110.81 85 3.73 3 8.38
PBMC Positive 0 – 1 2.76 0 – 1.4
Negative 24 85.445 48 4.15 3 8.86
HHV-6
PLASMA HHV-6A Positive 1** 100.33 0 – 0 – 0.5 **HC (1)
Negative 180 59.15 6 6.475 2 11.85 +HC (1)
PBMC HHV-6A Positive 1+ 100.33 0 – 0 – 1.3
Negative 71 42.44 4 5.16 0 –
PLASMA HHV-6B Positive 2§ 87.14 0 – 0 – 1.1 §HC (2)
Negative 179 59.43 6 6.475 2 11.85
PBMC HHV-6B Positive 0 – 0 – 0 – 0
Negative 72 43.74 4 5.16 0 –
HHV-7 (No serology data)∧
PLASMA Positive 0 0 HC (7), ME/CFS_MM
(9), ME/CFS_SA (9)Negative 182
PBMC Positive 25 49.0
Negative 51
(Continued)
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HHV-8 (No serology data)∧




∧There were no commercial ELISA kits available for HHV-7 and HHV-8.
HHV DNA Viral Concentration in Saliva in
People Living With ME/CFS
The absolute HHV viral DNA concentration load in participants
with ME/CFS was compared with that in HC for the four
detectable HHVs across the 6-month sampling time frame
(Figures 3C–F). There were no significant differences in absolute
viral DNA load for HSV (Figure 3C) or EBV (Figure 3D)
between clinical groups. HHV-6B viral DNA concentrations were
on average 6.2-fold higher in ME/CFS_SA patients than in HC:
the differences were significant at months 1 (P = 0.039), 3
(P = 0.030), and 5 (P = 0.029), with a trend toward higher
viral load across all time points (Figure 3E). There was a trend
toward higher HHV-6B DNA concentration in ME/CFS-MM
participants than HC, with borderline significance at months 3
(P = 0.073) and 5 (P = 0.080). Finally, HHV-7 viral loads were
significantly or borderline significantly higher in ME/CFS_MM
[at months 1 (P = 0.068), 3 (P = 0.054), 4 (P = 0.023), and 5
(P = 0.032)] and ME/CFS_SA patients [at month 6 (P = 0.073)]
compared to HCs, with a trend toward higher loads across all
timepoints for both ME/CFS_MM and ME/CFS _SA groups,
with an average 4.1-fold increase in ME/CFS-MM and 3.0-fold
increase in ME/CFS_SA compared to HCs across the months
(Figure 3F).
The Spearman correlation between plasma IgG concentration
(in biobanked samples) and salivary HHV viral DNA load
for each participant was analysed for EBV and HHV-6
(Supplementary Figure 3). There was no significant correlation
between EBV viral load and either EBNA or VCA antibody
concentration in people with ME/CFS or HC. Although, there
was a significant negative correlation between anti HHV-6 IgG
concentration and salivary HHV-6B DNA concentration in the
HC group, this was largely driven by one individual and no
correlation was seen in the ME/CFS participants. The low
correlation might reflect the time interval between serum and
saliva sampling.
There was no difference in salivary HHV viral load between
participants who had been deemed as HHV DNA-positive or
DNA-negative in the initial plasma/PBMC ddPCR screening
assay (Table 2) although, among the HCs, those who were
plasma/PBMC HHV DNA-positive were significantly younger
than those who were plasma/PBMC HHV DNA negative
(Table 2). One HC in whom HHV-6B was detected in plasma
had very high concentrations of HHV-6B DNA in saliva
but this was an outlier and may reflect a recent infection
(Supplementary Table 4). All people living with ME/CFS
in whom HHV-7 was detected in PBMC also had high
concentrations of salivary HHV-7 DNA (Table 2).
When stratifying participants by age, the salivary HHV-6B
DNA concentration was significantly higher in younger (<40
years) than older participants in the HC and ME/CFS_MM
groups but not the ME/CFS_SA group (Supplementary Table 5)
but there were no significant differences in HSV-1, EBV, or
HHV-7 DNA concentrations between age groups.
Salivary HHV Viral DNA Concentration
Through Time and During Acute Illness
Episodes in People With ME/CFS
Salivary DNA concentrations of HSV-1, EBV, HHV-6B, and
HHV-7 varied over time in individual participants (Figure 4).
Concentrations of HSV-1 and EBV DNA fluctuated month by
month in the majority of infected individuals with no obvious
differences between clinical groups, whereas, there was less
fluctuation in HHV-6B and HHV-7 DNA concentrations, with
more participants with ME/CFS than HC exhibiting persistently
higher viral loads (Figure 4A).
There was no discernible pattern of changing HHV DNA
concentrations during periods of worsening disease symptoms
in the seven ME/CFS participants (one MM case and 6 SA,
one of whom had two episodes of worsening symptoms)
who had an acute illness or worsening of disease symptoms
(Figure 4B): rather there was fluctuation in detection of all
four viruses during these episodes, with both increases and
decreases in viral load during exacerbated disease (Figure 4B and
Supplementary Figure 4).
HHV Co-Infections in People With ME/CFS
Over Time
We investigated changes in detection of viral DNA from co-
infecting HHV viruses over time in individual study participants
(Supplementary Figure 5 and Supplementary Table 6). At all
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FIGURE 3 | Herpes virus DNA prevalence and concentration in saliva from people living with ME/CFS, measured by ddPCR. (A) Percentage HHV prevalence in HC
(n = 16) and people with mild/moderate ME/CFS (ME/CFS_MM: n = 14) or severe symptoms (ME/CFS_SA: n = 16) at month 1. (B) Persistence of viral DNA positivity
throughout 6 months. The persistency (%) was calculated for each participant as the number of times HHV was detected divided by the total number of samples
collected over 6 months, multiplied by 100. HHV viral DNA concentration comparison between HC and ME/CFS patients. Each monthly viral DNA concentration in
saliva from participants with mild/moderate (ME/CFS_MM) or severe (ME/CFS_SA) disease was compared to HC across the 6 months for (C) HSV-1, (D) EBV,
(E) HHV-6B, and (F) HHV-7. Scatter dot plots show the median and the interquartile range. P-values < 0.1 (Mann-Whitney) are shown.
time points, HHV-7 was more frequently detected as the
only HHV present in saliva than any other HHV; HHV-7
together with HHV-6B, and HHV-7 together with EBV, as
dual combinations of HHV DNAs, and the triple combination
of HHV-7 together with HHV-6B and EBV, were also
frequently observed (Supplementary Figure 5A). The quadruple
combination (HHV-7 with HHV-6B, EBV, and HSV-1) and other
HHV combinations as dual or triple infections were detected
only rarely (Supplementary Table 6). The HHV-7 with HHV-
6B combination was significantly more frequently found in
ME/CFS_SA than in HC (chi square p < 0.05 at months 1 and
5), in accordance with the higher frequency of HHV-6B DNA
detection in severely affected ME/CFA patients. Dual detection
of HHV-7 with EBV was more frequent in ME/CFS_MM than in
ME/CFS_SA participants, with significant differences (p < 0.05)
at months 2 and 4 and a trend in the other months.
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TABLE 2 | HHV viral load in saliva of participants who were HHV DNA-positive or DNA-negative in the initial ddPCR screening assay of plasma and PBMC.
Month 1 Saliva ddPCR results Prevalence %
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People severely affected with ME/CFS could be broadly
and evenly separated into two subgroups, dependent on how
their combinations of salivary HHV DNA changed over time.
People with pattern 1 showed varying combinations of one
to four HHVs being detected over the 6-month time course,
whereas, people with pattern 2 showed relatively simpler and
more stable HHV positivity consisting of one to two HHVs
detectable (Supplementary Figure 5B). The majority of people
with mild/moderate ME/CFS symptoms (7/10) had the more
stable HHV repertoire pattern with only three ME/CFS_MM
participants fitting the fluctuating repertoire pattern (data
not shown).
Correlation of ME/CFS Symptoms With
Each Other and With Viral Load
To evaluate any association between disease symptoms and
salivary detection of HHV DNA, the numerically graded
responses to the clinical questions collected together with each
saliva sample were categorised into seven domains (PEM, pain,
sleep dysfunction, neurocognition, autonomic nervous system,
neuroendocrine system, or immune system) to yield seven
“symptom scores” for each sample. First, we compared symptom
scores by group (Figure 5A). HC individuals had low scores
across all symptom domains. People severely affected with
ME/CFS had significantly higher PEM scores (P = 0.003) and
a tendency toward greater autonomic dysfunction than the
ME/CFS_MM group, whereas, other symptoms did not differ
significantly between the two groups. We then examined the
Spearman correlation of the symptom scores with each other:
for all people with ME/CFS (i.e., ME/CFS_MM and ME/CFS_SA
combined: n = 30), all symptom scores significantly correlated
with each other (median of all r = 0.508, P < 0.01) (Figure 5B)
and symptom scores were significantly (P = 0.0007) more highly
correlated among patients who were mildly/moderately affected
by ME/CFS than among those severely affected with ME/CFS
(MM, median of r = 0.604; SA, median of r = 0.385, all P < 0.05
for ME/CFS_MM group comparisons, P < 0.05 for ME/CFS_SA
group except Sleep dysfunction vs. PEM P = 0.108 and vs. Pain
P = 0.238) (Supplementary Figure 6). Of the seven symptom
domain scores, autonomic symptoms were highly correlated
with neurocognition symptoms (r = 0.70) among all people
with ME/CFS, and these two symptom domain scores were
moderately correlated with other symptom scores (autonomic
symptoms vs. all others, median r = 0.586; neurocognition
symptoms vs. all others, median r = 0.582). In contrast, sleep
dysfunction symptoms were only weakly correlated with other
symptoms scores (median r = 0.348), except that among people
severely affected with ME/CFS sleep dysfunction was highly
correlated with neuroendocrine’ symptoms (r = 0.62). Finally
pain symptoms were highly correlated with neurocognition,
autonomic and immune related symptoms (r = 0.66, 0.66, 0.60,
respectively) in people severely affected with ME/CFS.
We investigated the correlation between salivary HHV DNA
concentration and symptom scores across the 6 months of the
study in people with ME/CFS (Supplementary Figures 6A–C)
and healthy controls; overall, the extent of correlation was
weak. Among people severely affected with ME/CFS, there were
weak correlations between EBV DNA concentration and three
symptom scores (pain, neurocognition, and autonomic: r = 0.25,
0.23, and 0.29, respectively, all P < 0.05), between HSV-1 DNA
concentration and autonomic symptoms (r = 0.24, P < 0.05),
and between HHV-7 DNA concentration and pain symptoms
(r = 0.25, P <0.05), and autonomic symptoms (r = 0.24,
P < 0.05). EBV DNA concentration correlated with HSV-1 DNA
concentration in people severely affected with ME/CFS (r= 0.27,
P < 0.01), whereas, HHV-6B correlated with HHV-7 (r = 0.22,
P < 0.05) (Supplementary Figure 6B). There were no significant
correlations between salivary HHV DNA concentration and
symptom scores among people mildly/moderately affected with
ME/CFS. This group showed only weak negative correlation
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FIGURE 4 | Change in herpesvirus DNA concentration in saliva in individual participants over time. (A) The monthly viral load of HSV-1, EBV, HHV-6B, and HHV-7
detected in saliva from month 1 (Jan 2018) to month 6 (Jun 2018), measured by ddPCR assay, is shown for individual HC, ME/CFS_MM and ME/CFS_SA study
participants. (B) The HHV viral load of HSV-1, EBV, HHV-6B, and HHV-7 in ME/CFS patients is shown on day 1, 3, and 5 of episodes when participants experienced
an acute illness or worsening of disease symptoms.
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FIGURE 5 | Disease symptom and correlation in people living with ME/CFS and Healthy controls. (A) Median score and IQR of seven ME/CFS symptom domains
across 6 months in people with mild/moderate (n = 14) or severe ME/CFS (n = 16) and HC (n = 16), based on questionnaires completed at the time of saliva sample
collection by participants. (B) Correlation matrix between seven ME/CFS symptom domain scores in people with ME/CFS (n = 30).
between EBV and HHV-6B salivary DNA concentrations (r =
−0.25, P< 0.05). Among the HC there were weak but statistically
significant correlations between detectable HHV-6B DNA in
saliva and neuroendocrine symptoms (r = 0.21, P < 0.05) and
between HSV-1 DNA concentration and both autonomic and
immunological symptoms (r= 0.36 and 0.22, respectively, all P<
0.05). This group also showed correlation between EBV or HHV-
6B and HHV-7 salivary DNA concentrations (r = 0.28 and 0.22,
respectively, all P < 0.05).
We next investigated the correlation between salivary
HHV DNA concentration and symptom scores in the two
subgroups of severely affected ME/CFS patients (pattern
1 and pattern 2, Supplementary Figure 5B) (Figure 6,
Supplementary Table 7). In the pattern 1 ME/CFS_SA
group (fluctuating levels of HHV DNA in saliva) there
were strong and highly significant associations between
HHV-6B DNA concentration and six symptom domain
scores (sleep dysfunction, pain, neurocognition, autonomic,
neuroendocrine and immune, r = 0.47, 0.52, 0.65, 0.50, 0.46,
and 0.41, respectively, all P ≤ 0.01). Three of these symptom
domains were also correlated with HHV-7 DNA concentration
(pain, neurocognition and autonomic, r = 0.49, 0.44, and
0.47, respectively, all P = 0.002 or < 0.001). In contrast,
in the pattern 2 ME/CFS_SA group (stable HHV DNA in
saliva), HHV-6B DNA concentration was negatively correlated
with pain, neurocognition and neuroendocrine scores (r =
−0.59, −0.43, and −0.42, respectively, all P < 0.01) whereas,
EBV DNA concentration was positively associated with pain,
neurocognition, and autonomic symptoms (r = 0.48, 0.40, and
0.39, respectively, P = 0.001, 0.008, and 0.010, respectively).
Moreover, neuroendocrine and immune system scores were
significantly higher in the pattern 1 group than the pattern 2
(P < 0.01) (data not shown). Finally, when people with ME/CFS
had an acute illness episode, during their sick days, the HHV-
6B DNA concentrations were positively correlated with sleep
dysfunction andHHV-7 DNA concentration (r=0.454, P< 0.05,
r = 0.548, P < 0.01, respectively; Supplementary Table 7). PEM
and Pain were negatively correlated with HHV-6B, r = −0.647,
P < 0.01, r = −0.426, P < 0.05, respectively). Interestingly,
in all seven patients reporting an acute illness or worsening of
symptoms, participants, autonomic symptoms were markedly
increased whereas, neuroendocrine symptoms were decreased
(Supplementary Table 7).
DISCUSSION
Using duplex droplet digital PCR, we have analysed the
prevalence and DNA load of human herpesviruses in the saliva
of ME/CFS patients and looked for associations with severity
of symptoms over time. In summary, HHV-7 was the most
frequently detected HHV in saliva and salivary HHV-7 DNA
concentrations were significantly higher in people with ME/CFS
than in healthy controls; HHV-6B was more frequently detected,
and with significantly higher viral loads, in people severely
affected with ME/CFS than in healthy controls and those with
mild/moderate ME/CFS, such that severely affected ME/CFS
patients weremore likely than other groups to beHHV-6B/HHV-
7 double-positive; andHHV-6B andHHV-7 viral loads correlated
with disease severity in a subgroup of people severely affected
with ME/CFS whose salivary HHV repertoire fluctuated over
the 6 months of the study, suggesting that HHV-6B and HHV-7
may trigger ME/CFS symptoms or be reactivated in concert with
worsening symptoms. Importantly, although, HSV-1 and EBV
were detected in some saliva samples, there were no consistent or
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FIGURE 6 | Correlations of salivary HHV DNA concentration with disease symptoms scores. (A) Correlation between monthly symptoms score and monthly HHV viral
DNA concentration in people with ME/CFS_SA (pattern 1, left panel; pattern 2, right panel). All participant’s monthly HHV viral DNA concentration and symptoms
score data were included in the correlation analysis. Each symbol represents an individual’s monthly sample. NB: Zero values are not shown on the graph due to the
logarithmic scale, but are included in the analysis. Spearman’s coefficient is denoted as r. The best-fit regression line, 95% confidence interval (grey area) and
prediction band (dotted line) are shown. (B) Correlation between symptom scores and EBV, HHV-6B, and HHV-7 DNA concentrations in saliva samples from
participants experiencing an exacerbation of symptoms.
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statistically significant differences in HSV-1 and EBV reactivation
between people with ME/CFS and healthy controls.
These findings are consistent with, and extend, previous data
linking EBV, HHV-6 andHHV-7 infection and reactivation to the
clinical course of ME/CFS [reviewed in (30)]. Frequent HHV-
6 and/or HHV-7 infection or reactivation has been reported in
chronic fatigue syndrome patients (31–34) and has been linked
to decreased cellular immune responses (31) and to ME/CFS
symptoms including PEM and lymphadenopathy (32). The
HHV-6A and HHV-6B primers used in our ddPCR assays allow
the discrimination between HHV-6 subtypes which historically
has not been possible serologically. Moreover, Chu et al. (35)
reported that one third of patients had a documented acute HHV
or B19 virus infection related to herpes viruses and B19 virus
associated withME/CFS onset. Although, the study reported here
is of small scale, the results are in accordance with previous data,
demonstrating that a large prospective epidemiological study
is warranted to test conclusively the aetiological link between
HHV reactivation and ME/CFS symptoms. Such a study should
address potential confounding factors such as age and gender in
relationship to ME/CFS development and presentation as well as
immune control of HHVs. Recent data have shown reactivation
of HHVs, including HHV-6, during Sars-CoV-2 infection (36),
opening up the possible role of HHVs in so-called “LongCOVID”
in which symptoms in many cases overlap those presented by
people with ME/CFS.
Saliva is a key transmission route for HHVs as the salivary
gland is a particularly permissive site for HHV replication.
We detected HSV-1, EBV, HHV-6, and HHV-7 DNA in saliva
samples, either singly or in combinations of up to 4 HHVs,
consistent with previous studies (37–40); HHV-7 has been
reported to be almost universally detected in saliva (41). The
prevalence of HSV-1, EBV, and HHV-7 in our healthy controls
was broadly similar to a previous report Miller et al. (40)
but the prevalence of HHV-6B (25%) was markedly lower
than the 93.5% prevalence of HHV-6 reported previously; this
difference may reflect the detection target (HHV-6B rather
than the whole HHV-6 genome), methodology or genuine
population differences. Furthermore, in all but one of our study
participants, detection of HHV DNA in saliva (evidence of
virus reactivation and shedding) was highly correlated with
detection of viral DNA in previously collected (baseline) samples
of PBMCs (where the virus may be latent) or plasma, indicating
that these are longstanding, persistent infections rather than
acute/recent infections. One of our healthy control participants
had very high plasma and salivary concentrations of HHV-
6B DNA which were positively correlated with immune-related
and autonomic symptoms: it is possible that this participant
had inherited chromosomally integrated HHV-6B which has
been reported to lead to ME/CFS symptoms in some people
(42). Another participant, with mild/moderate ME/CFS, had
persistently high salivary EBV DNA. In the current study design
it was not possible to test for active viral transcription or protein
synthesis alongside viral DNA quantification. Future studies
should investigate correlation between viral DNA concentration
in contemporaneous plasma, PBMCs and saliva samples, as
well as measurement of IgM and IgG to indicate recent
or historic infection, and host DNA load, as well as direct
measures of HHV reactivation (12, 43) and HHV epitope
mapping studies (34) in order to more fully interpret the
saliva data.
Herpesviruses maintain latent infections at different
anatomical sites. HHV-6 and HHV-7 remain dormant inside
leukocytes, mainly T cells, and their genomes integrate into
host chromosomal telomeres providing a mechanism for viral
reactivation via the release of telomeric circular DNA following
T cell activation in response to a heterologous infection (44, 45).
Furthermore, HHV-7 can reactivate HHV-6A/B while HHV-6
has been found to activate Epstein-Barr virus from latency
(46–48). HHV-6 and HHV-7 latency within leukocytes leads
to wide-ranging impacts on the immune system (4) including
changes in host cell transcriptomes and metabolism (49), down-
regulation of antigen presentation and modulation of cytokines
and chemokines (50, 51), impairment of NK cell function (52),
and enhancement of proinflammatory cytokine and chemokine
responses to Toll-like receptor 9 signalling (53). HHV-6
reactivation in ME/CFS patients can also lead to mitochondrial
fragmentation and severely compromised energy metabolism
(54); this may be linked to reported interactions between the
HHV-6BU95 early viral protein and themitochondrial GRIM-19
protein (55) that results in reduced mitochondrial membrane
potential and pronounced mitochondrial impairment. It has
also been postulated that persistent HHV infection/reactivation
during which effector T cells are controlled by regulatory T
cells may also lead to ME/CFS symptoms (56). The weak but
statistically significant correlations observed here between
reactivation of HHV-6, HHV-7, and EBV, and the correlations
between HHV viral loads and severity of disease symptoms in
ME/CFS patients, may thus reflect T cell activation either by one
of these HHVs or by another infectious agent; and/or HHV-
induced dysfunction of various cells of the immune system;
and/or direct or indirect effects of HHVs on mitochondrial
function. Whilst we did not observe any significant association
between HHV reactivation and episodes of disease exacerbation,
this may be due to the low number of acute disease episodes in
our study, and to the marked heterogeneity of ME/CFS patients.
Larger and longer studies will be needed to properly address this
hypothesis and identify potential triggers.
In summary, this pilot study demonstrates that it is possible
to recruit people living with ME/CFS and to collect biologically
relevant samples, longitudinally, even during periods of disease
exacerbation, opening up the prospect of conducting large-
scale studies to investigate the role of human herpes viruses
in ME/CFS pathogenesis. Our data indicate that HHV6-B and
HHV-7 are associated withME/CFS disease severity. Herpesvirus
reactivation might either be a cause or effect of ME/CFS
manifestation: either a disturbance in immune system function
caused by ME/CFS disease development enables a persistent
HHV viral infection to become reactivated, or the reactivation
of the virus might be the precipitating factor for the worsening
of ME/CFS symptoms. Many factors, such as co-infection,
long-term stress, immunosuppressive therapy, and autoimmune
disease can lead to HHV reactivation, which would fit with
heterogeneity seen in ME/CFS cohorts. Long-term, large-scale
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studies are warranted to determine cause vs. effect for the role
of HHVs in ME/CFS.
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